We describe the acute presentation and the long-term evolution of recurrent tumefactive lesions (TLs) in a patient with relapsing-remitting multiple sclerosis. Five TLs occurred on three different occasions over a period of 12 years and these were followed by 73 serial magnetic resonance images (MRI). TL evolution was described by means of magnetization transfer imaging (MTI) and cerebrospinal fluid tissue specific imaging (TSI) over the follow-up period. During the study period, the patient had three clinical relapses with only minimal disability progression. MTI demonstrated that only the peripheral portion of each TL reverted to pre-lesional MT ratios within six months' post-enhancement. Recurring TLs may present a similar pattern of evolution that may be associated with a long-term favourable clinical outcome.
Case history
Our case study aims at (1) delineating the acute appearance and recovery pattern of five tumefactive lesions (TLs), analyzed over 12 years using 73 magnetic resonance imaging (MRI) exams, and (2) describing the long-term clinical outcome of a relapsing-remitting multiple sclerosis (RRMS) patient presenting multiple TLs (Figure 1 (a-d) ). A 36-yearold woman presented to the National Institutes of Health (NIH) with bilateral leg numbness in September 1997. A year prior to that she had a spontaneously resolving optic neuritis. Diagnosis of clinically definite MS was made and she enrolled in a clinical trial investigating the efficacy of the altered peptide ligand, CGP77116 (APL). 1 After five months of therapy, she developed superior homonymous quadrantanopsia and TL1 (Figure 1(a) ). TL1 had started as a small enhancing lesion three months prior to evolving into a nodular TL with moderate edema, compression of the posterior horn of the right lateral ventricle, and minimal midline shift. TL1 enhanced for seven months total. APL was discontinued. The patient responded well to a 10-day course (1 gram/day) of intravenous methylprednisolone (IVMP). Therapy with 6,000,000 international units interferon beta-1a (IFNβ-1a) once weekly was initiated intramuscularly. In May 2000 (15 months later) she presented difficulty in retrieving words and weakness in the left extremities. Brain imaging showed a nodular TL2 and a partial-ring 2 TL3 (Figure 1(b) ) in the right anterior and left posterior fronto-parietal regions, respectively. These TLs had minimal mass effect toward the lateral ventricles but no midline shift. Both TLs enhanced for a total of four months. A stereotactic biopsy was performed on TL3. Biopsy was performed because of concerns that this recurrent pattern of TLs could represent a malignancy. TL3 was chosen because of its surgical accessibility. Immunohistochemistry showed a dense inflammatory infiltrate of lymphocytes with myeloss and reduced axons (Figure 1(e-j) ).
The patient tested negative for neutralizing antibodies against IFNβ. She was proposed adding azathioprine to IFNβ-1a but she preferred continuing IFNβ-1a alone. In October 2002, because of persisting contrast-enhancing lesion activity (Figure 1(d) (Figure 1(c) ) were incidentally seen during a 3.0 Tesla research imaging study. TL4 was located in the left frontal lobe adjacent to the lateral ventricle with no mass effect. TL5 appeared in the right medial parietal lobe with minimal mass effect on the posterior horn of the lateral ventricle. Both TLs had nodular shape and none exerted midline shift. Although the patient did not report new symptoms, because of the presence of the two TLs she underwent a 10-day course of IVMP. Glatiramer acetate was discontinued. IFNβ-1a at the dose of 44 micrograms subcutaneously three times per week was started in association with monthly IVMP for six months. The patient remained free from clinical relapses until May 2010 (54 months, study-year 12) when disability at the Expanded Disability Status Scale 3 was rated at 2.5. She has not returned to the NIH since.
TLs evolution
Image acquisition and processing details are reported in the online material. A voxel-based analysis of TL1 (representative example) showed a mild decline in magnetization transfer ratio (MTR) in normal-appearing white matter several months before the enhancement (Figure 2(a) ). During the TL acute phase, MTR showed a further sharp decrease. Significant recovery was seen within six months and was stable throughout the follow-up (Figure 2(b) ) but only voxels enhancing at the lesion periphery (Figure 2(c-e) ) returned to baseline MTR values. Two years after the acute enhancement of each TL, the percentage of recovering voxels was 61% (TL1), 51% (TL2), 38% (TL3, biased by scar tissue post-biopsy), 71% (TL4), and 62% (TL5). Only 27.5% (TL4) and 25.8% (TL5) of the central-enhancing voxels were visible in cerebrospinal fluid tissue-specific imaging (CSF-TSI) 4, 5 in the acute phase. Two years later, only 4.6% (TL4) and 5.9% (TL5) of these voxels remained hyperintense in CSF-TSI.
Discussion
The TL appearance and recovery patterns seen in our patient resemble the ones of type I and II active lesions described by previous authors. 6 These types of lesions generally start with profound blood-brain barrier damage, massive edema, demyelination, and pronounced axonal destruction. When the lesions mature edema resolves; there is profound remyelination throughout the lesions, but because of axonal injury in the center of the lesion, repair is incomplete. In our case, sharp decreases in MTR and hyperintense signal in CSF-TSI were seen during the TL enhancement and, as confirmed by histopathology, indicated severe myelin damage, inflammatory infiltrates, and axon decomposition. Over time, only MTRs of peripheral voxels reverted to pre-lesion values, consistent with the notion of an incomplete recovery and axonal injury predominantly in the central core of the TL.
In our patient, the first TL occurred during the administration of the experimental drug APL. 1 The relation between first TL appearance and APL is a unique aspect of our case compared to previous literature. It remains unknown, however, if the APL was the actual cause of multiple TL occurrences. Three elements do not appear to support this hypothesis. First is the fact that none of the other patients enrolled in the experimental clinical trial developed TLs. 1 Second, is the fact that three patients in the APL trial had MS exacerbations. Only in the other two patients, who experienced clinical exacerbations, were we able to mechanistically link these exacerbations to the increase in myelin basic protein (MBP) (83-99)-specific T cells, cross-reactive to the APL. 1 Third is the notion that as seen in our patient, TLs tend to present predominately in female RRMS patients and during the third decade of life. 7, 8 TL reoccurrence is rarely seen, however. In a large cohort of 54 MS patients with TLs followed for a median time of 38 months, TLs reoccurred twice in about 20% of the patients and three times in less than 2%. 9 The relatively high reoccurrence rate seen in our patient may be partially explained by the longer follow-up period.
In conclusion, we confirm that TLs may reoccur in MS. We demonstrate that when reoccurring, TLs may present with a homogenous imaging pattern of recovery over time and may be associated with an overall favorable clinical prognosis. (Figure 2(a) ) over the follow-up period for the whole TL1 (solid line), the peripheral region (dashed line), and the central core (dash-dot line). A sharp decrease in MTR affected almost the entire enhancing area in the acute phase (solid arrow). Smaller MTR declines preceded the acute phase by 12 months (dotted-line arrow). Signs of recovery were seen as early as six months after first TL appearance. We depict the percentage of TL1 voxels returning to baseline MTR (Figure 2(b) ) over the period of the follow-up. Enlarged triangular dots denote MRIs showing some enhancement in the region of the TL. Maps of the areas of lesion recovery are represented in Figure 2(c-e) , showing in Figure 2 (c) the entire lesion, in Figure 2 (d) voxels that did not recover, and in Figure 2 (e) voxels that recovered over time.
